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Abstract
Background: Adipose tissue is a large endocrine organ known to secret adiponectin, which has anti-diabetic, anti-
atherogenic, and anti-inflammatory properties. Adiponectin is widely involved in systemic disease, diabetes mellitus,
and cardiac infraction. This study aimed to investigate the involvement of adiponectin in intervertebral disc (IVD)
degeneration.
Methods: Adipose and IVD tissues were obtained from human patients undergoing surgery (n = 4) and from
skeletally mature Sprague–Dawley rats (n = 21). Tissues were stained immunohistochemically for adiponectin and
adiponectin receptors AdipoR1 and AdipoR2. Changes in adiponectin receptor expression with IVD degeneration
severity were then investigated using a rat tail temporary compression model. Rat IVD tissues were stained
immunohistochemically with AdipoR1 or AdipoR2, and immunopositive cell percentages were calculated. Rat
nucleus pulposus (NP) and annulus fibrosus (AF) tissues were isolated separately and treated with recombinant
adiponectin (Ad 0.1 or 1.0 μg/ml) and/or interleukin-1 beta (IL-1β) (0.2 μg/ml) for 24 h. The four groups were as
follows: control group (no treatment), IL-1β group (IL-1β-only treatment), IL-1β+Ad (0.1) group (IL-1β and
adiponectin [0.1 μg/ml] treatment), and IL-1β+Ad (1.0) group (IL-1β and adiponectin [1.0 μg/ml]). Real-time reverse
transcription-polymerase chain reaction was performed to evaluate messenger-RNA (mRNA) expression of tumor
necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6).
Results: Adiponectin was widely expressed in human subcutaneous and epidural adipose tissue. In rat IVD tissue,
adiponectin was not observed in NP and AF. However, both AdipoR1 and AdipoR2 were widely expressed in both
human and rat IVD tissues, with no significant differences in expression levels between receptors. Furthermore,
expression levels of AdipoR1 and AdipoR2 were gradually decreased with increased IVD degeneration severity.
Interestingly, mRNA expression levels of TNF-α and IL-6 were significantly upregulated by IL-1β stimulation. TNF-α
expression in the IL-1β+Ad 1.0 group was significantly lower than that in the IL-1β group in both NP and AF cells
(P < 0.05). Finally, IL-6 expression was not affected by adiponectin treatment in IVD cells.
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Conclusions: This study investigated for the first time the expression of adiponectin receptors in human and rat
IVD cells. The findings indicate that adiponectin produced by the systemic or epidural adipose tissue may be
involved in the pathomechanism of IVD degeneration.
Keywords: Adiponectin, Adiponectin receptor, Anti-inflammatory effect, Intervertebral disc, Degeneration, Animal
model
Background
Low back pain (LBP) is a highly debilitating disorder that
significantly impacts the workforce and increases med-
ical expenditure, resulting in high socioeconomic costs
worldwide [1]. Intervertebral disc (IVD) degeneration is
considered to be a major cause of LBP [2]. The cause of
IVD degeneration is multifactorial and heritable, with
overweight or obese conditions as known risk factors
[3]. Diabetes mellitus (DM) is also a global health prob-
lem, with several investigators recently reporting the in-
volvement of systemic diseases, like DM, in LBP [4, 5].
However, there are few reports concerning the relation-
ship between DM and IVD degeneration [6, 7]; there-
fore, this research topic remains unclear.
Adipose tissue is a large endocrine organ that secrets
various bioactive molecules, known as adipokines, in-
cluding tumor necrosis factor-α (TNF-α), adipsin, leptin,
resistin, and adiponectin [8]. Among these adipokines,
adiponectin was originally identified independently by
four researchers using different approaches [9, 10] and is
known to have anti-diabetic, anti-atherogenic, and anti-
inflammatory effects [11, 12]. Adiponectin exists in
abundance in the blood circulation. Interestingly, it is re-
ported that the plasma adiponectin level is remarkably
reduced in patients with DM [8].
Two subtypes of adiponectin receptor (AdipoR1 and
AdipoR2) have been identified by expression cloning of
complementary DNA encoding [13]. Both AdipoR1 and
AdipoR2 contain seven-transmembrane domains but are
structurally and functionally distinct from G protein-
coupled receptors [13]. AdipoR1 and AdipoR2 serve as
the major receptors for adiponectin in vivo, with Adi-
poR1 activating activated protein kinase (AMPK) path-
ways and AdipoR2 activating peroxisome proliferator-
activated receptor alpha (PPAR-α) pathways [14]. Re-
cently, a number of studies have reported adiponectin
receptor expression in various organs such as the brain
[15], adipose tissue [16], and cartilage [17]. However, ex-
pression of adiponectin in the IVD tissue of humans or
rats has not been previously investigated.
Patients with DM, presenting low-level plasma adipo-
nectin, often present with LBP [4, 5]. In the current study,
we hypothesized that the adiponectin pathway, and associ-
ated anti-inflammatory effect, may be associated with IVD
degeneration. We first assessed expression levels of
AdipoR1 and AdipoR2 in both human and rat IVD cells.
To determine the involvement of adiponectin in IVD de-
generation, we assessed changes in receptor expression
with disc degeneration using a rat tail temporary static
compression model, which reproduces different stages of
IVD degeneration [18]. The anti-inflammatory property of
adiponectin on IVD cells was also investigated.
Methods
Ethics statement
The collection and use of human IVD specimens were
approved by the Ethics Committee of Kobe University
Hospital. All samples were obtained in accordance with
the World Medical Association Declaration of Helsinki
Ethical Principles for Medical Research Involving Hu-
man Subjects. This study was approved by the Institu-
tional Review Board of Kobe University Graduate School
of Medicine. All patients provided written informed con-
sent. All animal procedures were performed under the
approval and guidance of the Animal Care and Use
Committee at the authors’ institution. Skeletally mature
male Sprague–Dawley (SD) rats (12 weeks old; CLEA
Japan, Tokyo, Japan) were used.
Assessment of adiponectin expression in human adipose
and rat IVD tissues
Subcutaneous and epidural adipose tissues were ob-
tained from four consenting patients (two males and
two females, 65.0 ± 12.4 years, range 48–77 years) during
surgical procedure (lumbar disc herniation: two cases;
lumbar spinal stenosis: two cases). None of the patients
had systemic diseases such as DM or rheumatoid arth-
ritis. Samples were fixed in 4% paraformaldehyde (PFA)
and rapidly frozen for ~15 s in liquid nitrogen prior to
being sectioned at a thickness of 15 μm.
IVD tissue was obtained from four male SD rats. IVD
tissue samples were fixed in 4% PFA and decalcified in
10% ethylenediaminetetraacetic acid (EDTA). After being
dehydrated in a graded series of alcohol, they were em-
bedded in paraffin and sectioned at 6-μm thickness.
Samples were then deparaffinized in xylene and rehy-
drated in a graded series of alcohol. All sections were
stained overnight (4 °C) with anti-mouse adiponectin
(Abcam, MA, USA) at a dilution of 1:100. After primary
antibody incubation, samples were washed three times
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with phosphate-buffered saline (PBS) and incubated for
1 h with secondary antibody (Molecular Probes, OR,
USA).
Immunohistochemical assessment of AdipoR1 and
AdipoR2 expression in human and rat IVD tissues
Four human IVD tissue samples were obtained from the
same four patients and during the same surgical proce-
dures as detailed above. All IVD tissue samples were
fixed in 4% PFA and decalcified in 10% EDTA. After be-
ing dehydrated in a graded series of alcohol, the samples
were embedded in paraffin and sectioned at 6-μm thick-
ness. The samples were then deparaffinized in xylene
and rehydrated in a graded series of alcohol. The sec-
tions were divided into two groups: one group was
stained with anti-goat AdipoR1 (Santa Cruz, CA, USA)
and the other with anti-rabbit AdipoR2 (Santa Cruz,
CA, USA) antibodies. These sections were incubated
with the primary antibodies at a dilution of 1:100 at 4 °C
overnight. Subsequently, the sections were treated at
room temperature for 1 h with peroxidase-labeled anti-
goat or anti-rabbit antibodies (Nichirei Bioscience,
Tokyo, Japan), respectively. A brown reaction product
was developed using peroxidase substrate 3,3′-diamino-
benzidine (DAKO), and counterstaining was performed
with hematoxylin. Images were immediately captured
using a BZ-9000 microscope (Keyence). Specimens were
evaluated and scored based on a semiquantitative ap-
proach to determine the percentage (%) of AdipoR1-
and AdipoR2-positive cells. Numbers of immunostained
cells were counted in at least three randomly selected
high-power fields of view (150 cells or more/view) for
each sample.
SD rat coccygeal IVD tissues (n = 4 animals; vertebral
body–disc–vertebral body) were obtained en bloc and
immunostained with AdipoR1 and AdipoR2 using the
aforementioned procedures.
Changes in adiponectin receptor expression using a rat
tail temporary static compression model
SD rats (n = 9) underwent intraperitoneal anesthesia,
and radiographs were taken to confirm disc levels and
heights. Rat tails were then affixed between the eighth
and tenth coccygeal vertebrae using an Ilizarov-type de-
vice with springs. Axial force was applied from the distal
side to produce a compressive stress of 1.3 MPa. This
stress corresponds closely to a transient disc loading
force produced by lifting a moderate weight in the hu-
man lumbar spine and induces morphological and bio-
chemical disc degeneration. Following surgery, rats were
divided into three groups (N = 3/group) according to
loading duration: D1 group (loaded for 1 day then
unloaded for 55 days), D7 group (loaded for 7 days then
unloaded for 49 days), and sham group (unloaded for
56 days). This rat tail temporary static model reproduces
different stages of IVD degeneration (D1: mild IVD de-
generation; D7: moderate IVD degeneration) [18]. All
IVD tissues were immunostained with AdipoR1 or
AdipoR2 as described above.
Cell culture and treatments
Coccygeal IVDs were aseptically dissected from eight SD
rats. The nucleus pulposus (NP) and annulus fibrosus
(AF) were then isolated separately. NP and AF cells were
pre-cultured for 7 days at 37 °C in 5% CO2 and 95% air
in complete tissue culture media containing Dulbecco’s
modified Eagle’s medium (DMEM; Sigma Aldrich, St.
Louis, MO, USA) supplemented with 10% fetal bovine
serum (FBS, Sigma- Aldrich), 25 μg/ml ascorbic acid,
100 U/ml penicillin, and 100 mg/ml streptomycin. After
pre-culture, the NP and AF cells were seeded into 6-well
plates for complete adhesion and grown to approxi-
mately 60–70% confluence. The NP and AF cells were
then treated with recombinant adiponectin (0.1 or
1.0 μg/ml; BioVision, Milpitas, CA, USA) and/or
interleukin-1 beta (IL-1β, 0.2 μg/ml; R&D Systems, Min-
neapolis, MN, USA) for 24 h. The wells were divided
into four groups as follows: (1) control group without
IL-1β or adiponectin (Ad); (2) IL-1β group treated with
IL-1β (0.2 μg/ml) only; (3) IL-1β+Ad (0.1) group treated
with both IL-1β (0.2 μg/ml) and adiponectin (0.1 μg/ml);
and (4) IL-1β+Ad (1.0) group treated with both IL-1β
(0.2 μg/ml) and adiponectin (1.0 μg/ml).
RNA extraction, reverse transcription, and quantitative
RT-PCR analysis
Cultured NP and AF cells were collected and total RNAs
were isolated using the RNeasy Mini Kit (Qiagen, Hil-
den, Germany) according to the manufacturer’s instruc-
tions. RNAs (0.1 μg) were reverse-transcribed in the
presence of oligo d(T) primer (Applied Biosystems, Fos-
ter City, CA, USA).
Relative messenger-RNA (mRNA) expression levels of
TNF-α and interleukin-6 (IL-6) were calculated by real-
time reverse transcription-PCR using the ABI Prism7500
sequence detection system (Applied Biosystems). Glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) mRNA ex-
pression was measured as an endogenous control [18].
SYBR green fluorescent dye and predesigned primers (all
obtained from Takarabio, Tokyo, Japan) were used ac-
cording to the manufacturer’s instructions. The primer
sequences used for PCR were as follows: GAPDH, sense
5′-GGCACAGTCAAGGCTGAGAATG-3′ and antisense
5′-ATGGTGGTGAAGACGCCAGTA-3′; TNF-α, sense
5′-TCAGTTCCATGGCCCAGAC-3′ and antisense 5′-G
TTGTCTTTGAGATCCATGCCATT-3′; and IL-6, sense
5′-ATTGTATGAACAGCGATGATGCAC-3′ and anti-
sense 5′-CCAGGTAGAAACGGAACTCCAGA-3′. The
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measurements were performed in duplicate, and mRNA
expression levels of each gene in each experimental group
were converted to a relative number representing the
amount of mRNA compared with the control group using
the 2−ΔΔCt method [19].
Statistical analysis
All values are expressed as means ± standard deviation
(SD). Analysis of variance (ANOVA) with Fisher’s least
significant difference (LSD) post hoc test was used to as-
sess changes within and between experimental groups.
Statistical significance was considered at a P value <0.05.
Statistical analyses were performed using PASW Statis-
tics 18 (IBM SPSS, Armonk, NY, USA).
Results
Adiponectin expression in human adipose tissues and rat
IVD tissues
In human adipose tissues, immunohistochemical stain-
ing demonstrated expression of adiponectin in both hu-
man subcutaneous and epidural adipose cells. The mean
percentage of positive adiponectin cells was 72.8 ± 14.9%
in the subcutaneous and 67.8 ± 19.5% in the epidural
adipose. No significant difference in adiponectin expres-
sion was identified between the subcutaneous and epi-
dural adipose cells.
Conversely, in rat IVD tissues, adiponectin was not
observed in both NP and AF tissues (Fig. 1).
Adiponectin receptor expression in human and rat IVD
cells
AdipoR1 and AdipoR2 expression was observed in both
NP and AF cells from human IVDs. The mean percent-
age of AdipoR1 and AdipoR2 was 39.4 ± 17.4% and 37.8
± 14.5% in NP cells and 51.6 ± 14.3% and 55.4 ± 21.6% in
AF cells, respectively. When expression levels of Adi-
poR1 and AdipoR2 were compared, no significant differ-
ences were observed for either NP or AF cells.
Expression of AdipoR1 and AdipoR2 was observed in rat
IVD cells: with a mean percentage of AdipoR1 and Adi-
poR2 at 79.6 ± 9.8% and 69.2 ± 15.8% in NP cells and
63.2 ± 17.5% and 66.2 ± 14.1% in AF cells, respectively.
Expression of AdipoR1 and AdipoR2 was diffuse
throughout the whole NP and AF. Localization of these
Fig. 1 Immunohistochemical staining of adiponectin in human subcutaneous and epidural adipose tissue (top left). Photomicrographs
demonstrating immunohistochemical localization of adiponectin in subcutaneous adipose tissue (left, A) and epidural adipose tissue (left, B); bars
= 100 μm. Percentage (%) of positive immunostained cells (top right). Immunohistochemical staining of adiponectin in rat IVD tissue (bottom): no
obvious staining was observed in either the NP or AF cells; bars = 100 μm
Terashima et al. Journal of Orthopaedic Surgery and Research  (2016) 11:147 Page 4 of 9
receptors was not observed in human or rat IVD
(Fig. 2).
Identifying adiponectin receptor expression changes
using a rat tail temporary static compression model
All animals tolerated surgery well and gained body
weight throughout the experiment. All springs main-
tained their compressive length and were fully recovered
immediately after release, indicating sustained axial load-
ing and no apparent buckling. Infection, skin necrosis,
neurological problems, or instrument failure were not
observed. As shown in Fig. 3, AdipoR1 and AdipoR2
were widely observed in the sham group in both the NP
and AF. Expression levels of AdipoR1 and AdipoR2 in
both the NP and AF were gradually decreased with in-
creased disc degeneration. AdipoR1 (% cells) decreased
in the NP from 81.8 ± 16.7% (sham group) to 48.8 ±
10.8% (D1 group) and 11.4 ± 7.0% (D7 group) (P < 0.05)
and in the AF from 67.6 ± 16.6% (sham group) to 30.8 ±
9.0% (D1 group) and 11.8 ± 5.5% (D7 group) (P < 0.05).
AdipoR2 (% cells) decreased in the NP from 70.8 ±
17.6% (sham group) to 25.8 ± 12.6% (D1 group) and 4.8
± 3.4% (D7 group) and in the AF from 68.8 ± 8.3% (sham
group) to 33.8 ± 10.4% (D1 group) and 7.8 ± 3.3% (D7
group) (P < 0.05). In summary, these results showed that
expression of both adiponectin receptors decreased in
Fig. 2 Immunohistochemical staining of AdipoR1 and AdipoR2 in human and rat IVDs. (Top) Photomicrographs demonstrating
immunohistochemical localization of AdipoR1 and AdipoR2 in both NP and AF: bars = 100 μm. (Bottom) Percentage (%) of positive
immunostained cells. Data were obtained from human IVD (N = 4) and rat IVD (N = 4), and expression is shown as mean + SD. R1 AdipoR1,
R2 AdipoR2
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the NP and AF in accordance to the severity of IVD
degeneration.
TNF-α and IL-6 mRNA expression in rat IVD cells
As shown in Fig. 4, mRNA expression levels of pro-
inflammatory cytokines, TNF-α and IL-6, were signifi-
cantly upregulated by IL-1β treatment in both NP cells
(+6.5-fold and +82.5-fold vs control, respectively; P <
0.05) and AF cells (+7.6-fold and +102.1-fold vs control,
respectively; P < 0.05). The mRNA expression level of
TNF-α in the IL-1β+Ad 1.0 group was significantly
lower than that in the IL-1β group in both NP (−48.0%)
and AF(−46.4%) cells (P < 0.05). Although mRNA ex-
pression of TNF-α in the NP and AF cells showed an
identical trend in the IL-1β+Ad 0.1 group compared
with the IL-1β group, a statistically significant difference
was not reached. Interestingly, mRNA expression of IL-6
was not affected by adiponectin treatment in both the
NP and AF cells. In summary, adiponectin inhibited IL-
1β-induced expression of TNF-α in both the NP and AF
IVD cells.
Discussion
This is the first study reporting expression of adiponec-
tin receptors (AdipoR1 and AdipoR2) in both human
and rat IVD cells. Using a rat tail temporary static com-
pression model, AdipoR1 and AdipoR2 expression were
found to decrease according to disc degeneration sever-
ity. After assessing the anti-inflammatory effects of adi-
ponectin on rat IVD cells, TNF-α expression induced by
IL-1β was significantly downregulated by adiponectin
treatment in cultured rat IVD cells.
AdipoR1 is known to be ubiquitously expressed, with
high expression in skeletal muscle, while AdipoR2 is
Fig. 3 Immunohistochemical staining of AdipoR1 and AdipoR2 according to disc degeneration using a rat tail temporary static compression
model. (Top) Photomicrographs demonstrating immunohistochemical localization of AdipoR1 and AdipoR2: bars = 100 μm in whole disc and NP
and AF photographs. (Bottom) Percentage (%) of positive immunostained cells. Data were obtained from N = 9 and expression is shown
as mean + SD
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most abundantly expressed in the liver. Although these
receptors are known to activate the AMPK and PPAR-α
pathways, respectively, their functions remain unclear.
Following reports of AdipoR1 and AdipoR2 expression
in articular cartilage, bone, and synovial tissue [17], the
current study investigated expression of these receptors
in both human and rat IVD cells by immunohistochem-
istry. AdipoR1 and AdipoR2 were expressed at compar-
able levels in IVD NP and AF cells in humans and rats.
With respect to adiponectin, expression was not ob-
served in rat IVD tissues. Adiponectin is thought to be
supplied by diffusion from systemic or epidural adipose
tissue. Whereas Khabour et al. reported that plasma adi-
ponectin has strong association with severity of IVD de-
generation, plasma adiponectin level was elevated in
patients with IVD degeneration [20]. The association be-
tween serum adiponectin and bone mineral density
(BMD) was also reported [21, 22]. In a recent review,
IVD degeneration is characterized by degradation of
aggrecan and collagen type II, promoted by an increase
in pro-inflammatory cytokines such as TNF, IL-1β, and
IL-6 [23]. In the current study, we focused on the anti-
inflammatory effect of adiponectin and hypothesized
that adiponectin uses this property as a protective role
in IVD degeneration. Our results showed that adiponec-
tin downregulated TNF-α expression induced by IL-1β
stimulation in cultured IVD cells. Shibata et al. also re-
ported that adiponectin inhibited TNF-α production
using cultured neonatal cardiac myocytes and fibroblasts
stimulated with lipopolysaccharide (LPS) [24]. They con-
cluded that adiponectin suppresses LPS-induced secretion
of TNF-α through a COX-2–prostaglandin E2–prostaglan-
din E2 receptor subtype 4 (EP4)-dependent pathway that is
independent of AMPK signaling. Taken together, these
and our current findings indicate that adiponectin elicits
its anti-inflammatory effect by suppressing pro-
inflammatory cytokines, especially TNF-α, and thus may
have the potential to resist the IVD degeneration process
due to pro-inflammatory cytokines.
We have previously reported the involvement of vari-
ous factors, such as pro-inflammatory cytokines SIRT1,
MMP-3, and kinematic mechanostress in IVD degener-
ation [25–30]. In 2014, Risbud and Shapiro reported that
pro-inflammatory cytokines, including TNF-α and IL-1β,
result in an imbalance in catabolic and anabolic re-
sponses leading to IVD degeneration and promote disco-
genic and radicular pain from the cytokine-mediated
degenerative cascade [23]. In the current study, we used
a rat tail temporary static compression model, represent-
ing the different stages of IVD degeneration, to investi-
gate the involvement of adiponectin in IVD
degeneration [18]. In the NP and AF, AdipoR1 and Adi-
poR2 expression gradually decreased with increased se-
verity of disc degeneration. Based on the current study
results, we consider that the anti-inflammatory function
of adiponectin on IVD cells gradually weakens with the
progression of IVD degeneration. In short, our findings
suggest that adiponectin may be involved in the patho-
mechanism of IVD degeneration.
DM is a systemic disease that causes degenerative
changes in many organs. Links between DM and IVDs,
or spinal structure degeneration, have been reported
Fig. 4 mRNA expression of TNF-α and IL-6 in rat NP and AF cells. A: control group without IL-1β and adiponectin; B: IL-1β group treated with
IL-1β (0.2 μg/ml) only; C: IL-1β+Ad (0.1) group treated with both IL-1β (0.2 μg/ml) and adiponectin (0.1 μg/ml); and D: IL-1β+Ad (1.0) group
treated with both IL-1β (0.2 μg/ml) and adiponectin (1.0 μg/ml)
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using animal models. Fields et al. reported that glycos-
aminoglycan (GAG) and water content in the NP were
significantly decreased in diabetic rats [6]. Also, diabetic
rats showed that elevated expression of hypoxia-
inducible genes and catabolic markers in the IVDs coin-
cided with increased oxidative stress. Illien-Junger et al.
reported that IVD height was significantly decreased in
diabetic compared with non-diabetic mice [7]. DM is
strongly associated with low plasma adiponectin levels
and high incidence of LBP [12]; therefore, a biological
approach using adiponectin may represent a suitable
treatment option.
Several limitations of this study exist. The anti-
inflammatory effect of adiponectin on rat and human
degenerative IVD cells was not investigated. In addition,
the function of adiponectin on the homeostasis of IVD
cells needs to be determined in vivo. Finally, a suitable
DM animal model should be used to determine the in-
volvement of adiponectin in LBP of DM patients.
In conclusion, we have demonstrated expression of
adiponectin receptors in the NP and AF tissues of hu-
man and rat IVD, the levels of which were determined
by IVD degeneration severity. Adiponectin inhibited the
TNF-α expression induced by IL-1β stimulation in rat
NP and AF cells. Because adiponectin was not observed
in the NP and AF cells, adiponectin is most likely sup-
plied from the systemic or epidural adipose tissues and
may be involved in IVD cell homeostasis.
Conclusions
The expression of adiponectin receptors in the NP and
AF tissues of human and rat IVD was observed. The ex-
pression levels were determined by IVD degeneration se-
verity. Adiponectin inhibited TNF-α expression induced
by IL-1β stimulation in rat NP and AF cells. Adiponectin
was not observed in NP and AF cells; adiponectin is
most likely supplied from the systemic or epidural adi-
pose tissues. Adiponectin may have a potential to be in-
volved in IVD cell homeostasis.
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